Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry
Insight Molecular Diagnostics announced the publication of favorable head-to-head data in Clinical Chemistry comparing its GraftAssure test to a competing NGS assay. The study demonstrated 99.2% agreement at the clinical threshold of 0.5%, while GraftAssure showed superior analytical sensitivity with a lower limit of quantification of 0.04%.
Key figures
- Samples
- 55
- Patients
- 18
- Rcv percent
- 41%
- Copies per ml
- 4
- Median ddcf DNA
- 0.17%
- Graftassure llq
- 0.04%
- Clinical threshold
- 0.5%
- Agreement percentage
- 99.2%
- Competitor llq range
- 0.12%-0.23%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.